Endo High Intensity Statin Selection Ascvd Risk Factors

---
name: endo-high-intensity-statin-selection-ascvd-risk-factors
description: Recommends choosing high-intensity statins in patients with atherosclerotic cardiovascular disease, or those with risk factors for atherosclerotic cardiovascular disease or risk-enhancing factors. Trigger phrases include: "Patient with established ASCVD", "Assessing need for high-intensity statin in high-risk patient", "Selecting statin intensity based on risk profile".
---

# Select high-intensity statin for atherosclerotic cardiovascular disease or risk factors

## STEP 1 — Gather Information
Collect history of ASCVD, type 2 diabetes mellitus, cardiovascular risk factors (hypertension, smoking, LDL‑C ≥70 mg/dL, low HDL‑C, family history of premature ASCVD, CKD), risk‑enhancing factors (lipoprotein(a) ≥50 mg/dL, metabolic syndrome, inflammatory conditions), current LDL‑C level, age, pregnancy status, renal function, and drug interactions.  
Proceed to assess for established ASCVD.

## STEP 2 — Rule In / Rule Out
If established ASCVD is present → recommend high-intensity statin; if ASCVD absent → proceed to evaluate for type 2 diabetes and cardiovascular risk factors.

## STEP 3 — Classify or Stratify
If patient has type 2 diabetes mellitus with at least one cardiovascular risk factor, or possesses any risk‑enhancing factor → classify as high‑intensity statin candidate; otherwise → classify as lower‑risk candidate.

## STEP 4 — Decide
For high‑intensity statin candidates, initiate high‑intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) plus lifestyle modification; for lower‑risk candidates, consider moderate‑intensity statin or lifestyle modification based on LDL‑C level and shared decision‑making.

## Clinical Guardrails / Mimics / Pitfalls
- Do not initiate statins in pregnancy or when trying to become pregnant.  
- When selecting a statin, consider renal clearance: pitavastatin, pravastatin, and rosuvastatin have partial renal excretion; atorvastatin, fluvastatin, lovastatin, simvastatin are hepatically cleared.  
- Avoid high‑intensity statin in active liver disease or unexplained persistent ALT/AST >3× ULN.  
- Watch for drug interactions (e.g., macrolides, cyclosporine, grapefruit juice) that increase statin toxicity.  
- Do not rely solely on LDL‑C goal without evaluating risk‑enhancing factors.  
- In severe hypertriglyceridemia (>500 mg/dL), address triglycerides first before statin initiation.

## Concrete Clinical Example
A 62‑year‑old woman with type 2 diabetes, hypertension, LDL‑C 145 mg/dL, no prior ASCVD, and lipoprotein(a) 60 mg/dL (risk‑enhancing factor) has T2D plus a CV risk factor (hypertension) and an elevated Lp(a). According to the guideline, a high‑intensity statin is recommended. Prescribe atorvastatin 40 mg daily with lifestyle modification.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674